INTRODUCTION
Mantle cell lymphoma (MCL) is a well-defined and aggressive B-cell non-Hodgkin's lymphoma that is genetically characterized by the t(11;14)(q13;q32) chromosomal translocation, which results in constitutive overexpression of CYCLIN D1.
1-3 CYCLIN D1 overexpression is considered to be a hallmark of MCL, and is closely correlated with the proliferative rate of these malignant cells. 4 Because CYCLIN D1 overexpression has been shown to be the most common feature of MCL, PD0332991 (palbococlib), a selective CDK4/6 (cyclin-dependent kinases 4 and 6) inhibitor, 5 has been tested in phase I/II clinical trials as a targeted therapy for MCL. Unfortunately, as a single agent, PD0332991 was reported to be cytostatic, and hence resulted in only stabilization of the disease with very few objective clinical responses. 6, 7 Despite these shortcomings, this agent has been found to sensitize MCL cells to other cytotoxic drugs owing to the fact that MCLs frequently exhibit lesions in other signaling pathways, including those mediated by the B-cell receptor, phosphatidylinositol 3 kinase (PI3K), WNT, NOTCH and tumor growth factor-β. 8, 9 Of these, dysregulated PI3K signaling is one of the most widely studied and represents an attractive druggable target.
Class I PI3Ks are the major activators of the AKT serinethreonine kinase and are subdivided into class IA and IB kinases. 10 Of the three class IA subtypes, PI3K-α, PI3K-β and PI3K-δ, both the α and δ isoforms have critical roles in immune signaling of normal cells. Although PI3k-δ is lineage restricted, expressed at high levels in B lymphocytes and transmits signals from the B-cell receptor, PI3K-α has a ligand-independent role in this process. Furthermore, both isoforms are mediators of agonist-independent, constitutive B-cell receptor signaling that occurs in MCL. [11] [12] [13] Studies have shown that MCLs constitutively activate the PI3K-AKT-mTOR (PI3K-AKT-mammalian target of rapamycin) pathway and that this signaling module has a key role in the aggressive blastoid variant of the disease. [13] [14] [15] Furthermore, in the case of refractory disease, both PI3K-α and PI3K-δ are also involved in ligand-independent activation of this pathway. 13 Ibrutinib (PCI-32765, Imbruvica), an inhibitor of the Burton's tyrosine kinase (BTK), has been remarkably successful in the treatment of chronic lymphocytic leukemia and has recently been approved for the treatment of certain refractory or relapsed MCL cases. Notably, this drug effectively induces complete remission in~21% of these patients 16 and is thought to do so, in part, by indirectly inhibiting PI3K-δ-mediated signals. As a result, several PI3K-δ inhibitors are now in various stages of clinical trials for the treatment of MCL and other B-cell malignancies. 17, 18 In spite of ibrutinib's efficacy, acquired resistance to the drug is beginning to emerge in the clinic. Whole-exome sequencing has revealed the presence of a single point mutation in the BTK ibrutinib binding site, C481S, which results in enhanced BTK and AKT activities in ibrutinibtreated patients with relapsed MCL. 19 Furthermore, subsets of patients that exhibit primary resistance or respond temporarily to the drug underscore the need to overcome alternate mechanisms of ibrutinib resistance.
Owing to the near-complete dysfunction of the CYCLIN D1/ CDK4/retinoblastoma (Rb) pathway and activation of the PI3K/AKT prosurvival pathway in most MCLs, recent studies have focused on combination therapies targeting both signaling modules. These studies have shown that treatment of MCL cells with PD0332991 induces G 1 arrest of cells and sensitizes them to selective PI3K-δ inhibitors, such as GS-1101 (idelalisib, CAL-101). 20 It is hypothesized that cells that are blocked in G 1 by CDK4/6 inhibition allows for sustained inhibition of PI3K-δ that is unlikely to be overcome by compensation of other PI3K isoforms. 19, 20 Towards the goal of inhibiting both CYCLIN D/CDK4/Rb and PI3K-δ in MCL, we recently developed a dual inhibitor of both pathways, ON123300, 21 and examined its effects on the growth and apoptosis of MCL cell lines. Our studies show that unlike PD0332991, treatment with ON123300 was cytotoxic and induced apoptosis of MCL cell lines and patient-derived MCLs. Our studies also show that ON123300 was effective in reducing the tumor burden in mouse xenograft models of MCL in the absence of adverse side effects.
MATERIALS/SUBJECTS AND METHODS

MCL patient samples
Primary human lymphoma samples were obtained either as part of a standard excisional biopsy or from peripheral blood samples from patients at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) with informed and written consent for tissue banking following a protocol approved by the Institutional Review Board (MSSM IRB no.11-1669) and in accordance with the Declaration of Helsinki. Specimens were processed to viable, sterile single-cell suspensions. Briefly, lymph node tissue was diced and forced through a metal sieve in a laminar flow hood into RPMI medium. Peripheral blood mononuclear cells or disaggregated MCL biopsy cells were pelleted by low-speed centrifugation, resuspended in media composed of 90% fetal bovine serum and 10% dimethyl sulfoxide (Sigma, St Louis, MO, USA), frozen slowly in the vapor phase of liquid nitrogen in multiple cryovials and stored in liquid nitrogen.
Cell lines
Cell lines were obtained from ATCC (Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium or RPMI (Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum and penicillin-streptomycin at 37°C under humidified conditions and 5% CO 2 . All cell lines tested negative for mycoplasma. To determine GI 50 values, cells were seeded at a density of 2.5 × 10 3 cells/0.1 ml per well of a 96-well plate. The compounds were added 24 h postplating at the indicated concentrations. Cell counts were determined from duplicate wells 96 h posttreatment. The total number of viable cells was determined using the Cell Titer Blue assay in conjunction with the GloMax plate reader (Promega, Madison, WI, USA).
Reagents and antibodies
Tumor necrosis factor-α was purchased from R&D Systems (Minneapolis, MN, USA; catalog no. 210-TA/CF). ON123300 was obtained from Onconova Therapeutics Inc. (Newtown, PA, USA) PD0332991, U0126 and QNZ were purchased from Selleckchem (Houston, TX, USA 
Kinase assays and western blot analysis
Kinase assays were performed as described earlier using recombinant proteins. 21 For whole-cell extracts derived from cell lines, cells were grown as indicated and lysed in NP40 cell lysis buffer (20 mM Tris, pH 7.4/250 nM NaCl/5 nM EDTA/50 mM NaF/1 nM Na 3 VO 4 /1% NP40/0.02% NaN 3 ) (Invitrogen). Patient-derived samples were incubated with ammonium chloride to remove red blood cells and the remaining cells lysed in RIPA buffer (25 mM Tris-HCl, pH 7.5/150 mM NaCl/1 mM EDTA/1 mM EGTA/1% NP40/1% SDS/2.5 mM sodium pyrophosphate/1 nM β-glycerophosphate/1 mM Na 3 VO 4 /1 mM leupeptin). Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes and subjected to western blot analysis using the indicated antibodies. Proteins were visualized using an Odyssey imaging system (LI-COR Biosciences, Lincoln, NE, USA).
Flow cytometric analysis
To determine cell cycle distribution, ethanol-fixed cells were washed with phosphate-buffered saline, resuspended in phosphate-buffered saline and incubated with RNase and propidium iodide at 37°C for 20 min. DNA content was measured using a FACS Calibur (BD Biosciences, San Jose, CA, USA) and the data analyzed using FlowJo (Treestar, Ashland, OR, USA). Annexin V staining of patient-derived material was performed using the FITC-Annexin V Apoptosis Detection Kit I (BD Biosciences). All data were acquired using an LSRFortessa (BD Biosciences) and analyzed using Cytobank (https://www.cytobank.org/).
Animal studies
To determine the maximum-tolerated dose of ON123300, female CD-1 mice (10-12 weeks of age) were injected intraperitoneally with a single dose of 100 or 200 mg/kg of ON123300. Signs of toxicity and body weights were monitored and recorded over the next 7 days. In a second study, 200 mg/kg ON123300 was administered via intraperitoneal injection for 5 consecutive days. Signs of toxicity and body weights were monitored and recorded over the next 10 days (n = 3 per group).
ON123300 plasma level concentrations were determined using female CD-1 mice (10-12 weeks of age). Mice were treated with ON123300 (50 mg/kg) dissolved in water via intraperitoneal injection or oral gavage (per os). Mice were killed at 10 min, 30 min, 1, 2, 4 and 8 h postadministration. Blood was collected by heart puncture into heparinized tubes containing 10 μl of 0.5 M EDTA and plasma was obtained following centrifugation for 10 min at 10 000 r.p.m. Plasma samples were analyzed by liquid chromatography/mass spectrometry using an Agilent 1200 HPLC/Agilent Triple Quad (Agilent Technologies, Santa Clara, CA USA). Area under the curve was calculated according to the trapezoidal rule: (1/2) (C 1 +C 2 )(t 1 − t 2 ) (n = 2 per time point).
For unblinded tumor xenograft assays, 1 × 10 7 Z138C cells were implanted subcutaneously into female nu/nu mice (12 weeks of age). Tumors were allowed to reach 100 mm 3 in size before the animals were randomly assigned to treatment groups. Five mice per group were treated with ON123300 (100 mg/kg) or vehicle (water) daily or every alternate day in two independent experiments. Tumor volumes and body weights were recorded as indicated. Tumor volumes were calculated using the following equation: (4/3)((L+W)/4) 
Statistical analysis
Statistical analysis was performed using a standard, unpaired, two-tailed Student's t-test. Data are graphed as mean ± s.d.. Results were considered significant as P ⩽ 0.05.
RESULTS
Derivation of a small-molecule inhibitor of MCL growth
We recently synthesized a large number (~3000) of novel ATP mimetics, some of which contained the basic backbone shown in Figure 1a and exhibited potent CDK4 inhibitory activity. 21 These compounds were tested in in vitro tissue culture growth inhibitory (concentration for 50% of maximal inhibition of cell proliferation (GI 50 )) assays against a panel of cell clines representing a variety of tumor types. This screen revealed that one of these compounds, ON0123300, exhibited 10-to 100-fold higher cytotoxicities against MCL cell lines as compared with those of other tumors (Table 1) . Subsequent testing of this compound by Reaction Biology Corp. (Malvern, PA, USA) for activity against a series of 285 functional kinases revealed that ON123300 is a multikinase inhibitor, 21 with highest activity against CDK4 and ARK5 (Table 2) , two kinases intimately associated with growth, survival and metastasis of human tumor cells. 22, 23 In addition to these kinases, this compound was shown to inhibit PI3K-δ, with a half-maximal inhibitory concentration (IC 50 ) of 144 nM ( Table 2 ). The kinase inhibition profile of ON123300 along with the synthetic procedures used to synthesize ON123300 have been published earlier. 21 Inhibition by CDK4 kinase activity by ON123300 To confirm the observation that CDK4 and PI3K-δ are targets of ON123300, we independently tested its activity in in vitro kinase assays using recombinant CDK4 and PI3K-δ (Figures 1b and c) . Our results showed that ON123300 is a potent inhibitor of CDK4, with an IC 50 of 3.8 nM, with little inhibitory activity against CDKs 1, 2, 5 and 8 (data not shown). As a positive control, we used PD0332991, a commercially available CDK4 inhibitor, which is highly selective towards CDK4 and CDK6, and is currently in various phases of clinical trials. 5, 7 Kinase inhibition assays showed that PD0332991 showed similar inhibition of CDK4 with an IC 50 of 5.36 nM (Table 2) . However, when these assays were performed using PI3K-δ, ON123300 inhibited the kinase with an IC 50 of 144 nM, whereas PD0332991 failed to show any inhibitory activity ( Figure 1c and Table 2 ).
Effect of ON123300 and PD0332991 on cell cycle progression and induction of apoptosis of MCL cells We next examined the effect of ON123300 and PD0332991 treatment on the cell cycle progression of MCL cell lines. For these studies, Z138C cells were cultured in the presence of increasing concentrations of ON123300 or PD0332991 for 24 h. The cells were then harvested and subjected to propidium iodide staining and flow cytometric analysis. Figure 2a shows the distribution of cells in various phases of the cell cycle. Dimethyl sulfoxide-treated cells served as negative controls. In the absence of drug, the majority of cells were in the G 1 phase of the cell cycle, with smaller percentages of the population in the S and G 2 phases (Figure 2a Dual inhibition of Rb and PI3K pathways by ON123300 in MCL SKA Divakar et al eventually accumulated in the sub-G 1 phase, suggesting an induction of apoptosis (Figure 2a ). To determine whether higher concentrations of ON123300 induced apoptosis in MCL cells, the levels of caspases 3, 7 and 9, as well as PARP cleavage, were determined by western blot analysis. The results presented in Figures 2b and c show that while there is no evidence of apoptosis in PD0332991-treated cells, we could readily see PARP cleavage in cells treated with ON123300 at concentrations ⩾ 2.5 μM for 24 h. We also observed decreases in the levels of full-length forms of caspases 3, 7 and 9, which are cleaved into their active forms upon the onset of apoptotic cell death.
Because ON123300 induced growth arrest and cell death over a 96-h period at concentrations of 25-50 nM, we repeated these studies using lower concentrations of the compound. These studies showed that incubation of the Granta 519 and Z138C cell lines with PD0332991 for 72-96 h did not show any PARP cleavage, whereas similar incubation of these cells with identical concentrations of ON123300 readily resulted in PARP cleavage (data not shown). These results confirm previous studies 5, 20, 24 and suggest that while PD0332991 induces effective growth arrest of MCL cell lines, it is not accompanied by apoptosis. On the other hand, while ON123300 triggers growth arrest at lower concentrations in a manner similar to PD0332991, at higher concentrations, this compound induces apoptosis of MCL cell lines.
Status of cell cycle regulatory proteins in ON123300-treated cells
It is now well established that the Rb family of proteins (pRb, Rb2/ p107 and p130) are primary targets of CDK4. 7 It is therefore highly likely that phosphorylation of Rb family proteins is inhibited owing to inhibition of CDK4 in MCL cells treated with PD0332991 or ON123300. To determine the effects of PD0332991 and ON123300 on Rb and its related proteins, Granta 519 and Z138C cells were treated with increasing concentrations of ON123300 or PD0332991 for 24 h. Whole-cell extracts were subjected to western blot analysis using antibodies directed against Rb and p130 and their phosphorylated forms, as well as CDK4, CDK2 and p21. The results of this study, presented in Figure 3 , showed that both compounds (ON123300 and PD0332991) inhibited the phosphorylation of pRb and p130 in a dose-dependent manner. Although the levels of CYCLIN D1 declined as a function of ON0123300 concentration, these results are in agreement with previous studies showing that inhibition of PI3K/AKT/mTOR signaling leads to loss of CYCLIN D1 expression.
14,15 P107 levels were extremely low in both cell lines, making it difficult to determine the effects of both ON0123300 and PD0332991 on its phosphorylation status (data not shown). Although the levels of CDK4 and CDK2 were unaffected in cells treated with ON123300 and PD0332991, we consistently observed loss of p21 levels in ON123300-treated cells, which was not readily seen in cells treated with PD0332991, that appears to be a consequence of PI3K pathway inhibition described below. These results suggest that both PD0332991 and ON123300 inactivate the Rb pathway in the two MCL cell lines studied here with equal efficiency.
Effect of ON123300 on the PI3K/AKT/mTOR pathway Because ON123300 inhibits PI3K-δ activity, we next examined the phosphorylation status of players in the PI3 Kinase pathway in cells treated with ON123300 and PD0332991. As predicted, there was no discernable change in the phosphorylation status of AKT, mTOR, 4EBP1 and S6RB in PD0332991-treated Granta 519 and Z138C cells (Figure 4) . However, we readily detected inhibition of AKT Ser473 phosphorylation, which is mediated by members of the PI3K family, 25, 26 in ON123300-treated cells. Inhibition of AKT phosphorylation subsequently resulted in an inhibition of mTOR phosphorylation at Ser2481, a site that is phosphorylated by AKT. 25 Similarly, phosphorylation of downstream AKT/mTOR targets, 4EBP1 and S6RB, 27, 28 were inhibited in ON123300-treated cells. In addition, we also noted inhibition of FOXO1 phosphorylation, which is also known to be a target of mTOR, 29 in cells treated with ON123300 (Figure 4) . Dephosphorylation of FOXO1 positively regulates the transcriptional activity of this growth suppressor protein, which has been shown to activate apoptotic pathways and cell cycle arrest. 30 Taken together, these studies provide a molecular basis for the observed induction of apoptotic pathways seen in cells treated with ON123300.
Effect of ON123300 on the mitogen-activated protein kinase and NF-κB pathways Because ON123300 is a multikinase inhibitor, it is possible that some of its antitumor activity might be associated with its ability to inhibit mitogen-activated protein kinase and/or NF-κB pathways. To test this possibility, we examined the phosphorylation status of MEK and ERK1, 2 kinases whose activation is mediated by growth factor receptors. These studies, presented in Supplementary Figure 1, show that neither ON123300 nor PD0332991 has any effect on the phosphorylation status of MEK or ERK kinases, whereas U0126, a known MEK inhibitor that served as a positive control, potently inhibited MEK and ERK phosphorylation in Granta 519 and Z138C cell lines. We next examined the effects of ON123300 and PD0332991 on the phosphorylation status of p65 (NF-κB), a recently identified druggable target in MCL, 31 in exponentially growing Z138C cells and observed no change in the phosphorylation status of this protein (Supplementary Figure 2A) . As a positive control, we used HeLa cells that were treated with 5 ng/ml of tumor necrosis factor-α, which are known to activate the NF-κB pathway in response to this chemokine. Following treatment with ON123300 or PD0332991, cells were incubated with tumor necrosis factor-α for 5 min and the level of p65 NF-κB phosphorylation was examined by western blot analysis. These studies, presented in Supplementary Figure 2B , show that ON123300 and PD0332991 had little or no effect on the phosphorylation status of p65, whereas QNZ (EVP4593), a known inhibitor of the NF-κB pathway, induced strong inhibition of p65 phosphorylation.
Effect of ON123300 on primary patient-derived MCL viability To test the effects of ON123300 on primary tumor samples, we collected peripheral blood by apheresis from MCL patients with leukemic disease. Two samples, one sensitive to ibrutinib (MEM1) and a second sample from a patient with ibrutinib-resistant MCL (MEM2), were used in these studies. The cells were treated with increasing doses of ON123300 and the level of apoptosis measured using Annexin V staining. Figure 5a shows the increase in Annexin V-positive cells of both samples following exposure to ON123300 for 24 h. Although the onset of apoptosis in both the ibrutinib-sensitive and -resistant samples was observed in cells treated with as little as 500 nM of the compound, nearly 100% of cells stained Annexin V positive in the presence of 5 μM ON123300 (Figure 5a) .
We also analyzed the levels of Rb and AKT phosphorylation in these samples. Figure 5b shows that both primary MCL samples exhibited reductions in the levels of Rb and AKT phosphorylation. Furthermore, the phosphorylation of S6RB was also inhibited, suggesting inhibition of the PI3K-AKT-mTOR pathway (Figure 5b) . 28 These studies are in agreement with those presented for the Granta 519 and Z138C MCL cell lines and confirm that ON123300 effectively blocks both the CDK4/Rb and AKT/PI3K pathways that are critical for MCL growth and survival.
Safety pharmacology and in vivo efficacy
We next performed studies to determine the maximum-tolerated dose of ON123300 in mice. Three CD-1 mice were injected intraperitoneally with 100 or 200 mg/kg of ON123300. Signs of toxicity and body weights were monitored and recorded over the next 7 days. No signs of toxicity or weight loss were observed with a survival rate of 100%. A second study, whereby 200 mg/kg ON123300 was administered for 5 consecutive days, showed that this dosing regimen did not exhibit any signs of toxicity and had a survival rate of 100% for at least 10 days postadministration (data not shown). We also performed liquid chromatography/mass spectrometry to determine the pharmacokinetics of ON123300 in the plasma. These studies show that the area under the curve values were 7.18 and 2.78 μg/ml per h in mice that received the drug via intraperitoneal injection and oral gavage (per os), respectively, which reflect concentrations of 16.71 (intraperitoneally) and 6.47 μM/ml per h (per os) in the plasma. Because the plasma concentration of ON123300 was higher in animals that received the compound via intraperitoneal injection, we used this route of administration for subsequent mouse xenograft assays.
To determine the in vivo efficacy of ON123300, we used a nude mouse model of MCL where Z138C cells were injected into nude mice and allowed to grow to~100 mm 3 in size. Mice with tumor xenografts were randomly assigned into two treatment groups (n = 5 per group) and treated daily with either water (vehicle) or ON123300 (100 mg/kg). Body weights and tumor volumes from two independent studies were recorded and plotted as a function of time ( Figure 6 ). Figure 6b shows a representative image of tumors in control and ON123300-treated mouse cohorts on day 14 of experiment no. 2. As seen here and in Figure 6a , treatment with ON123300 significantly inhibited (P o 0.05) tumor growth over a 2-week period, suggesting that this compound is a potent inhibitor of MCL proliferation in vivo. In addition, daily treatment with ON123300 did not cause a significant reduction in the total body weights of ON123300-treated animals (Figure 6c ). (The increase in the body weights of the untreated animals is likely attributable to the rapid growth of tumors.) These results, in addition to those obtained in vitro, suggest that ON123300 is an effective therapeutic agent in MCL with minimal-associated toxicity.
DISCUSSION
The pathogenesis of MCL is characterized by cell cycle dysregulation, with CYCLIN D1 overexpression being a hallmark of this disease. Cyclin D1 complexes with its catalytic partners, CDK4/6, driving Rb protein phosphorylation and G 1 cell cycle progression. 32 Initial studies with PD0332991 (palbococlib), a selective small-molecule inhibitor of CYCLIN D-associated CDK4/6 and -resistant (MEM2) primary MCLs. Cells were treated with increasing concentrations of ON123300 for 18 h, and western blot analysis was performed as described in Figure 2 .
inhibitor activity, 5 demonstrated potent inhibition of Rb phosphorylation and G 0 /G 1 cell cycle arrest in the absence of any associated apoptosis. 24 In accordance, the drug was cytostatic in a phase I/II clinical trial for MCL and resulted in disease stabilization with an 18% overall response rate. 6 Although PI3K signaling is activated in MCL, in a phase I trial, idelalisib (GS-1101), a selective PI3K-δ inhibitor, was also modestly effective as a single agent in patients with refractory disease. 33 In spite of these outcomes, PD0332991 has been shown to sensitize MCL cell lines to PI3K-δ inhibition, in part, by enhancing the effect of the loss/reduction of AKT phosphorylation when the cells are arrested in the G 1 phase. 17, 19, 20 In this communication, we examined the effects of ON123300, a dual inhibitor of CDK4 and PI3K-δ on MCL cell growth and compared its activity with PD0332991, a highly specific CDK4/6 inhibitor. Our results show that while both inhibitors induce G 1 arrest of MCLs, only ON123300 elicits an apoptotic response from these tumor cells. The G 1 arrest mediated by the two compounds studied here is clearly because of inhibition of phosphorylation of members of the Rb family, a direct result of CDK4 and CDK6 inhibition by both compounds. Our results also show that in contrast to PD0332991, ON123300 acts as a potent inhibitor of the PI3K/AKT/mTOR pathway, leading to the activation of apoptotic pathways, as assayed by caspase activation and PARP cleavage. Our results also show that ON123300 treatment results in inhibition of FOXO1 phosphorylation, a target of mTOR ( Figure 4 ). Dephosphorylation of FOXO1 is known to regulate the transcriptional activity of this protein, which has been shown to activate apoptotic pathways and cell cycle arrest. 15, 30 Taken together, these studies provide a molecular basis for the observed induction of apoptosis ON123300-treated cells.
Safety studies in mice suggest that ON123300 is orally bioavailable and is minimally toxic when administered orally or intraperitoneally. The in vivo efficacy of ON123300 was examined using Z138C cells grown as xenografts in nude mice. These studies, presented in Figure 6 , showed that treatment of these tumor-bearing mice with ON123300 markedly inhibited tumor growth over a 14-day period, further suggesting that this compound could be a possible candidate for the initiation of clinical trials. Previous studies have demonstrated that ON123300 readily crosses the blood-brain barrier, 34, 35 and considering the fact that a small percentage of MCL patients experience lymphomatous spread to the meninges and central nervous system, 36 this agent could also be useful for patients with CNS involvement.
Recent studies have shown that constitutive activation of B-cell receptor signaling via PI3Ks is essential for the proliferation of a large portion of MCLs, particularly in relapsed or refractory disease. 37 This observation was further supported by the finding that ibrutinib, a covalent inhibitor of BTK, has a profound effect on disease progression of MCL patients. 16 MCLs that acquire resistance to or relapse from treatment with ibrutinib because of the BTK C481S mutation, as well as those that exhibit primary resistance to the drug show increased AKT and ERK activation. 19, 38 Interestingly, these drug-resistant MCLs exhibit a bias in CDK4-driven proliferation, which is sensitive to combined inhibition of the CDK4 and PI3K pathways. 19 We examined the effects of ON123300 on primary tumor samples that were derived from MCL patients who either responded to ibrutinib or who acquired resistance following ibrutinib treatment. Both cell types were sensitive to the proapoptotic effects of ON123300 as measured by increased Annexin V staining and reductions in the levels of phospho-Rb, phospho-AKT and S6RB phosphorylation, consistent with inhibition of the mTOR pathway. These results suggest that ON123300 is likely to be an effective treatment option for both ibrutinib-responsive and -resistant patients.
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